immunogenicity for cattle vaccinated with FMD A22 vaccine adjuvanted with oil and Poly IC Vaccine Differentiation Group Lloyd Jones K Mahapatra M Herbert R ID: 1033265
Download Presentation The PPT/PDF document "Enhanced potency and" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Enhanced potency and immunogenicity for cattle vaccinated with FMD A22 vaccine adjuvanted with oil and Poly I:CVaccine Differentiation GroupLloyd- Jones K., Mahapatra M, Herbert R, Parekh K, Babu A, Paton D, Taylor G and Parida S*.
2. Current FMD Vaccines and challenges for control Killed inactivated vaccineNot quick enough to induce protectionShort lived immunityNot very stable Does not give sterile immunityVaccinated animals may become infected with or without signs of disease
3. Current FMD vaccines ( A May 97 and SAT2)Oh et al., 2012 Plos One
4. Improvement of existing oil (ISA 206) adjuvanted vaccines by adding new adjuvants - to increase humoral and CMI (IFN-gamma up-regulation by CD4+ and CD8+ cells)?.Question we need to address
5. Non-Vaccinate control cattleA22 Iraq+ ISA-206 controlA22 Iraq+ ISA-206 + AbISCO adjuvantA22 Iraq+ ISA-206 + poly I:C adjuvantA22 Iraq+ ISA-206 + R848 adjuvantA22 Iraq+ ISA-206 + MPLA adjuvantA22 Iraq+ ISA-206 + R848+ MPLA adjuvantAdjuvant Trial Design1.2.3.4.5.6.7.
6. Adjuvant Trial Timeline0A22 Iraq Vaccination + new generation adjuvant(sub-optimal dose- 2 micro gram)7142128A22 Iraq FMDV ChallengeCull140Saliva and nostril swabs taken weeklyBlood: heparinised and clotted taken weeklyRectal temperatures taken dailyClinical symptoms scored dailyDays post vaccinationDays post challenge7
7. Percentage of clinical protection
8. Poly (I:C) and AbISCO had significantly increased neutralizing antibodies compared to the ISA-206 (28 dpv time point)
9. Detection of virus replication by NSP testNon Structural Protein antibody ELISA
10. Excretion of virus in nasal swabs qPCR
11. (28 dpv time point) The inclusion of new generation adjuvants enhanced A22 specific proliferation
12. IFN-gamma from CD4+ and CD8+ PBMC(G)(H) Gating Strategy
13. SummaryAchieved an increased potency and immunogenicity in Poly (I:C) and AbISCO treated groups with suboptimal antigen dose. Significantly elevated neutralizing antibodies.Indication of IFN-gamma up-regulation by CD4+ and CD8+ cells in Poly (I:C) group.On-going work-to measure duration of immunity
14. CollaboratorsMadhan MohanNagendra KumarV A SrinivasanAnita MilicicSarah GilbertAdrian HillRichard ReeveDan HaydonAcknowledgementsIIL